Flow Pharma
Warrensville Heights, US · Delaware corporation
Biotech
Founders & leadership
RM
Reid Martin RubsamenExecutive Officer, Director
RM
Reid Michael RubsamenExecutive Officer, Director
TB
Thomas BradyExecutive Officer
LJ
Lester John LloydExecutive Officer, Director
PS
Pamela SteeleDirector
AT
Anthony TufaroDirector
TB
Tikoes BlankenbergDirector
BO
Babatunde OtulanaDirector
Reported raises · per SEC filings
Form D private placements▶$225KraisedAug 2024 · 3 investors · BiotechnologyRule 506(b)
▶$225KraisedAug 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Pamela SteeleDirector
- Anthony TufaroDirector
- Reid Martin RubsamenExecutive Officer, Director
- Tikoes BlankenbergDirector
- Babatunde OtulanaDirector
- Offering amount
- $40M
- Amount sold
- $225K
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$180KraisedNov 2022 · 8 investors · BiotechnologyRule 506(c)
▶$180KraisedNov 2022 · 8 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Gil Van BokkelenExecutive Officer
- Reid Martin RubsamenExecutive Officer, Director
- Tikoes BlankenbergDirector
- Thomas BarnishExecutive Officer
- Stephen FarrDirector
- Charles Vincent HerstExecutive Officer
- Tom BradyExecutive Officer
- Pamela SteeleDirector
- Babatunde OtulanaDirector
- Offering amount
- $10.5M
- Amount sold
- $180K
- Finders' fees
- $500K
- Placement agents
- Carleton McKenna Advisors, LLC
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$2.3MraisedFeb 2018 · 42 investors · BiotechnologyRule 506(b)
▶$2.3MraisedFeb 2018 · 42 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Reid Michael RubsamenExecutive Officer, Director
- Thomas BradyExecutive Officer
- Lester John LloydExecutive Officer, Director
- Amount sold
- $2.3M
- Minimum investment
- $5K
- Proceeds to insiders
- $300K
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedFeb 2018 · 17 investors · BiotechnologyRule 506(b)
▶$1.1MraisedFeb 2018 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Reid M RubsamenExecutive Officer, Director
- Lester J LloydExecutive Officer, Director
- Amount sold
- $1.1M
- Minimum investment
- $12.5K
- First sale
- Apr 2011
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Department of DefenseOffice for Chemical and Biological Defense | Phase IISTTR | 2020 | $537.5K |
| Department of DefenseOffice for Chemical and Biological Defense | Phase ISTTR | 2018 | $136.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.